8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
Apr 22, 2026·SEC
Maze Therapeutics, Inc.(MAZE)Earnings, Financials & Key Ratios
MAZE•NASDAQ
$28.43
Price updated Jun 27, 2026
AboutMaze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.Show more
- Revenue$0-100.0%
- EBITDA-$140M-330.8%
- Net Income-$131M-351.0%
- EPS (Diluted)-3.05-4020.3%
- ROE-47.52%-194.1%
MAZE Price & Volume
Maze Therapeutics, Inc. (MAZE) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Erratic Revenue Streams
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Trial Funding Gap
"Maze Therapeutics faces a precarious outlook as its reliance on sporadic milestone payments, such as the $20.0 million recognized in 2026Q1, fails to offset the substantial R&D expenditures required to sustain its Compass platform. The loss of key strategic partnerships has significantly increased the firm's reliance on its $198.8 million cash reserve, heightening the probability of future dilutive equity financing. Investors should monitor the company's ability to achieve clinical milestones without the support of a stable, recurring commercial revenue model."
Verdict Logic
the company's fundamental instability is underscored by a persistent free cash flow burn of $39.2 million in 2026Q1 and the absence of a sustainable, recurring revenue stream to support its long-term clinical development.
MAZE Growth Metrics
Maze Therapeutics, Inc. (MAZE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-88.06%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-335.93%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-4396.88%
Return on Capital
10 Years-49.77%
5 Years-49.77%
3 Years-37.71%
Last Year-48.08%
MAZE Recent Earnings
Maze Therapeutics, Inc. (MAZE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/11 qtrs (50%)●Beat Revenue 1/11 qtrs (100%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.45-4.7%
$0.43
Rev
$20M+88.2%
$11M
Q2 2026
Mar 25, 2026Metric
Actual
Est
EPS
$0.65+11.0%
$0.73
Rev
—
$375,000
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.66+10.8%
$0.74
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.77+2.5%
$0.79
Rev
—
$3M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.45vs $0.43-4.7% | $20Mvs $11M+88.2% |
| Q2 2026 | Mar 25, 2026 | $0.65vs $0.73+11.0% | —vs $375,000 |
| Q4 2025 | Nov 6, 2025 | $0.66vs $0.74+10.8% | — |
| Q3 2025 | Aug 12, 2025 | $0.77vs $0.79+2.5% | —vs $3M |
Based on last 11 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Maze Therapeutics, Inc. (MAZE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $28.43 | $1.57B | -9.32 | -100% | — | -47.52% | — | |
| $30.77 | $3.03B | -5.28 | 20.13% | -91.03% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $104.50 | $6.92B | 76.28 | 15.24% | 9.48% | 5.13% | — | |
| $34.81 | $3.58B | -42.98 | 120.01% | -49.17% | -5.89% | — | |
| $16.68 | $1.87B | -4.38 | 16.92% | -597.04% | -57.27% | — |
Compare MAZE vs Peers
Maze Therapeutics, Inc. (MAZE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MAZE SEC Filings & Documents
Maze Therapeutics, Inc. (MAZE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when MAZE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MAZE Frequently Asked Questions
Maze Therapeutics, Inc. (MAZE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Maze Therapeutics, Inc.'s revenue?
Maze Therapeutics, Inc. (MAZE) reported $20.0M in revenue for fiscal year 2025.
How fast is Maze Therapeutics, Inc. growing?
Maze Therapeutics, Inc. (MAZE) saw revenue decline by 100.0% over the past year.
Is MAZE profitable?
Maze Therapeutics, Inc. (MAZE) reported a net loss of $122.5M for fiscal year 2025.
Dividend & Returns
What is MAZE's return on equity?
Maze Therapeutics, Inc. (MAZE) has a return on equity (ROE) of -47.5%. Negative ROE indicates the company is unprofitable.
What is Maze Therapeutics, Inc.'s free cash flow?
Maze Therapeutics, Inc. (MAZE) had negative free cash flow of $122.1M in fiscal year 2025, likely due to heavy capital investments.